NEW YORK (GenomeWeb) – Belgian molecular diagnostics firm Biocartis reported today that its first-half 2016 revenues fell 7 percent year over year on lower collaboration revenues.

The firm reported total revenues of €6.1 million ($6.9 million) versus €6.6 million for the first half of 2015. Its product sales jumped 63 percent to €2.7 million from €1.7 million, due to a 314 percent year-over-jump increase in cartridge sales. Sales for its Idylla molecular diagnostics systems were down 21 percent to €988,000 from €1.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.